Hematopoietic Stem Cell TransplantationTransplantation, HomologousGraft vs Host DiseaseBone Marrow TransplantationTransplantation ConditioningHematologic NeoplasmsHematopoietic Stem CellsStem Cell TransplantationTransplantation, AutologousTissue DonorsTransplantation ChimeraGraft vs Leukemia EffectPeripheral Blood Stem Cell TransplantationTreatment OutcomeLeukemiaGraft vs Tumor EffectBusulfanRecurrenceWhole-Body IrradiationHistocompatibility TestingHistocompatibilityRetrospective StudiesGraft SurvivalMyeloablative AgonistsChimerismLeukemia, Myeloid, AcuteImmunosuppressive AgentsStem CellsHematologic DiseasesMyelodysplastic SyndromesLymphocyte TransfusionAnemia, AplasticVidarabineCord Blood Stem Cell TransplantationAllograftsBone MarrowHLA AntigensBone Marrow CellsLiver TransplantationCytomegalovirus InfectionsRemission InductionTime FactorsAcute DiseaseSiblingsHepatic Veno-Occlusive DiseasePrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myelogenous, Chronic, BCR-ABL PositiveCombined Modality TherapySurvival AnalysisSurvival RateTransplantation ImmunologyTransplantation, IsogeneicT-LymphocytesLymphocyte DepletionDisease-Free SurvivalHematopoiesisMinor Histocompatibility AntigensFollow-Up StudiesMultiple MyelomaCyclophosphamideKidney TransplantationLymphoproliferative DisordersCystitisSevere Combined ImmunodeficiencyLeukemic InfiltrationOpportunistic InfectionsMice, Inbred C57BLCytomegalovirusImmunocompromised HostHematopoietic Stem Cell MobilizationFlow CytometryAntilymphocyte SerumLeukemia, MyeloidNeoplasm, ResidualFatal OutcomeSalvage TherapyRisk FactorsAntigens, CD34ImmunosuppressionPrognosisCyclosporineGraft RejectionMycosesBronchiolitis ObliteransBlood Group IncompatibilityAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesCell DifferentiationCell TransplantationChronic DiseaseMesenchymal Stem Cell TransplantationHeart TransplantationPhotopheresisIncidenceCytarabinePrimary MyelofibrosisGanciclovirMelphalanFetal BloodSurvivors